Literature DB >> 11760149

G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required.

J M Zaucha1, E Zellmer, G Georges, M T Little, R Storb, B Storer, B Torok-Storb.   

Abstract

Stable mixed donor/host hematopoietic chimerism can be uniformly established in dogs conditioned with 200 cGy TBI before dog leukocyte antigen (DLA)-identical marrow transplantation and immunosuppressed with a short course of mycophenolate mofetil (MMF) and cyclosporine (CSP) after the transplantation. A further decrease in the TBI dose to 100 cGy or the elimination of MMF in this model results in graft rejection. Here we asked whetherthe addition of G-CSF-mobilized peripheral blood mononuclear cells (G-PBMC) to marrow grafts would enhance donor engraftment in dogs conditioned with 100 cGy TBI and given postgrafting immunosuppression with CSP alone. Using this model, 7 of 9 dogs given only marrow cells rejected their grafts within 8 to 17 weeks after transplantation. In contrast, the addition of unmodified G-PBMC to marrow grafts resulted in stable mixed donor/host chimerism in 5 of 8 dogs studied (P = .06). However, addition of the CD3-depleted fraction of G-PBMC, which contained both CD34 cells and CD14 cells, resulted in engraftment in only 1 of 7 recipients. We conclude that adding G-PBMC to marrow grafts replaced the requirement of MMF and 100 cGy of TBI, and that CD3 cells were required to facilitate engraftment of marrow cells in DLA-identical recipients, whereas the additional CD34 cells present in G-PBMC were not sufficient for this effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11760149     DOI: 10.1053/bbmt.2001.v7.pm11760149

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  15 in total

1.  Pharmacological immunosuppression reduces but does not eliminate the need for total-body irradiation in nonmyeloablative conditioning regimens for hematopoietic cell transplantation.

Authors:  Marco Mielcarek; Beverly Torok-Storb; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-08       Impact factor: 5.742

2.  Evaluation of posttransplant methotrexate to facilitate engraftment in the canine major histocompatibility complex-haploidentical nonmyeloablative transplant model.

Authors:  Monica S Thakar; Erlinda B Santos; Theodore A Gooley; George Sale; Rainer Storb; Hans-Peter Kiem; Brenda M Sandmaier
Journal:  Transplantation       Date:  2010-07-15       Impact factor: 4.939

Review 3.  Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives.

Authors:  Marco Mielcarek; Brenda M Sandmaier; David G Maloney; Michael Maris; Peter A McSweeney; Ann Woolfrey; Thomas Chauncey; Lyle Feinstein; Dietger Niederwieser; Karl G Blume; Stephen Forman; Beverly Torok-Storb; Rainer Storb
Journal:  J Clin Immunol       Date:  2002-03       Impact factor: 8.317

4.  Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation.

Authors:  Yun Chen; Takahiro Fukuda; Monica S Thakar; Brian T Kornblit; Barry E Storer; Erlinda B Santos; Rainer Storb; Brenda M Sandmaier
Journal:  Cytotherapy       Date:  2011-08-17       Impact factor: 5.414

5.  Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model.

Authors:  Lauri Burroughs; Marco Mielcarek; Marie-Térèse Little; Gary Bridger; Ron Macfarland; Simon Fricker; Jean Labrecque; Brenda M Sandmaier; Rainer Storb
Journal:  Blood       Date:  2005-08-16       Impact factor: 22.113

6.  Transmission and expansion of HOXB4-induced leukemia in two immunosuppressed dogs: implications for a new canine leukemia model.

Authors:  Monica S Thakar; Xiao-Bing Zhang; Brian C Beard; George E Sale; Erlinda B Santos; Laura Peterson; Hans-Peter Kiem; Brenda M Sandmaier
Journal:  Exp Hematol       Date:  2009-07-17       Impact factor: 3.084

7.  Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis.

Authors:  Motoaki Shiratsuchi; Seiichi Motomura; Yasunobu Abe; Satoshi Shiokawa; Junji Nishimura
Journal:  Clin Rheumatol       Date:  2008-05-16       Impact factor: 2.980

8.  Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model.

Authors:  Sandra Lange; Simone Altmann; Bettina Brandt; Carsten Adam; Franziska Riebau; Heike Vogel; Volker Weirich; Inken Hilgendorf; Rainer Storb; Mathias Freund; Christian Junghanss
Journal:  Exp Hematol       Date:  2009-01       Impact factor: 3.084

9.  Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioning.

Authors:  Scott S Graves; William Hogan; Christian S Kuhr; Razvan Diaconescu; Michael A Harkey; George E Georges; George E Sale; Eustacia Zellmer; Szczepan W Baran; Szczepan Baran; Christoph Jochum; Brad Stone; Rainer Storb
Journal:  Blood       Date:  2007-03-16       Impact factor: 22.113

10.  Canine DLA-79 gene: an improved typing method, identification of new alleles and its role in graft rejection and graft-versus-host disease.

Authors:  G M Venkataraman; D Geraghty; J Fox; S S Graves; E Zellmer; B E Storer; B J Torok-Storb; R Storb
Journal:  Tissue Antigens       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.